News
Gilead Wins $69M Default Judgment in HIV Drug Counterfeit Case
A federal judge in the Eastern District of New York has awarded Gilead Sciences Inc. more than $69 million in damages and a permanent injunction in a trademark counterfeiting case involving fake HIV treatments.
The court adopted a magistrate judge's recommendation after multiple defendants failed to respond to the complaint. Gilead alleged that the defaulting parties acquired authentic medication bottles from patients, refilled them with incorrect pills, applied counterfeit seals and labels, and sold the products to pharmacies through falsified distribution records.
The scheme targeted Gilead's Biktarvy and Descovy brands among others. The court found liability under the Lanham Act for trademark infringement and counterfeiting, determining that the defendants used Gilead's registered marks on substandard products that posed health risks.
In addition to monetary damages, the injunction bars the defendants from further use of Gilead's marks or sale of counterfeit products. The ruling follows a preliminary injunction issued earlier in the proceedings.
This outcome highlights ongoing enforcement efforts by pharmaceutical companies against counterfeit drug networks that infiltrate legitimate supply chains.
Sources: https://www.law360.com/articles/2551067/gilead-obtains-69m-judgment-in-counterfeit-hiv-drug-case https://ipwatchdog.com/2026/11/17/gilead-wins-69-million-damages-permanent-injunction-against-defaulting-defendants-in-hiv-counterfeiting-ring/